| Market Cap | 107.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -16.73M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -11.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -44.00% |
| Recommedations | - | Quick Ratio | 0.03 | Shares Outstanding | 15.48M | 52W Low Chg | 17.00% |
| Insider Own | 52.55% | ROA | - | Shares Float | 18.96M | Beta | - |
| Inst Own | 4.77% | ROE | - | Shares Shorted/Prior | 15.62K/- | Price | 3.17 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 156,953 | Target Price | - |
| Oper. Margin | - | Earnings Date | May 15 | Volume | 116,255 | Change | -7.31% |
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.